Literature DB >> 6173239

Stereoselectivity of presynaptic autoreceptors modulating dopamine release.

S Arbilla, S Z Langer.   

Abstract

The effects of the (R)- and (S)-enantiomers of sulpiride and butaclamol were studied on the spontaneous and field stimulation-evoked release of total radioactivity from slices of rabbit caudate nucleus prelabelled with [3H]dopamine. (S)-Sulpiride in concentrations ranging from 0.01--1 microM enhanced the electrically evoked release of [3H]dopamine while (R)-sulpiride was 10 times less potent than (S)-sulpiride. Exposure to (S)-butaclamol (0.01--1 microM) but not to (R)-butaclamol (0.1--10 microM) enhanced the field-stimulated release of [3H]dopamine. The facilitatory effects of (S)- and (R)-sulpiride and (S)-butaclamol on the stimulated release of the labelled neurotransmitter were observed under conditions in which these drugs did not modify the spontaneous outflow of radioactivity. Only the active enantiomers of sulpiride and butaclamol antagonized the inhibition by apomorphine (1 microM) of the stimulated release of [3H]dopamine. Our results indicate that the presynaptic inhibitory dopamine autoreceptors modulating the stimulation-evoked release of [3H]dopamine in the caudate nucleus are, like the classical postsynaptic dopamine receptors, chemically stereoselective.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6173239     DOI: 10.1016/0014-2999(81)90105-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Presynaptic regulation of the electrically evoked release of endogenous dopamine from the isolated neurointermediate lobe or isolated neural lobe of the rat pituitary gland in vitro.

Authors:  K Racké; A Grosshans; S Sirrenberg; K Ziegler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

2.  Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

3.  The weaver mutant mouse as a model of nigrostriatal dysfunction.

Authors:  J R Simon; B Ghetti
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

Review 4.  Dopamine and glutamate in Huntington's disease: A balancing act.

Authors:  Véronique M André; Carlos Cepeda; Michael S Levine
Journal:  CNS Neurosci Ther       Date:  2010-04-08       Impact factor: 5.243

5.  Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites.

Authors:  M P Martres; P Sokoloff; M Delandre; J C Schwartz; P Protais; J Costentin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

6.  D2-dopamine receptor-mediated inhibition of intracellular Ca2+ mobilization and release of acetylcholine from guinea-pig neostriatal slices.

Authors:  H Fujiwara; N Kato; H Shuntoh; C Tanaka
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

7.  Differential effects of the stereoisomers of 3PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum.

Authors:  S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

8.  Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus.

Authors:  K Starke; L Späth; J D Lang; C Adelung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

9.  A functional response to D1 dopamine receptor stimulation in the central nervous system: inhibition of the release of [3H]-serotonin from the rat substantia nigra.

Authors:  S Benkirane; S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

10.  Modulation of [3H]-dopamine released by different frequencies of stimulation from rabbit retina.

Authors:  M L Dubocovich; J G Hensler
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.